TY - JOUR
T1 - Cord blood transplantation in children with haematological malignancies
AU - Bertaina, Alice
AU - Bernardo, Maria Ester
AU - Caniglia, Maurizio
AU - Vinti, Luciana
AU - Giorgiani, Giovanna
AU - Locatelli, Franco
PY - 2010
Y1 - 2010
N2 - Umbilical cord blood transplantation (UCBT) is largely used to treat children affected by haematological malignant disorders. In comparison to bone marrow transplantation (BMT), advantages of UCBT include lower incidence and severity of graft-versus-host disease, easier procurement and prompter availability of cord blood cells, and the possibility of using donors having HLA disparities with the recipient. The large experience accumulated so far has shown that UCBT offers to children a probability of cure at least comparable to that of patients transplanted with bone marrow cells. Since it has been demonstrated that an inverse correlation between the number of nucleated cord blood cells infused per kg recipient body weight and the risk of dying for transplantation-related causes exists, recently developed strategies aimed at increasing the number of cord blood progenitors and at favouring stem cell homing could further optimize the outcome of children with leukemia or other malignancies receiving UCBT. (C) 2010 Elsevier Ltd. All rights reserved.
AB - Umbilical cord blood transplantation (UCBT) is largely used to treat children affected by haematological malignant disorders. In comparison to bone marrow transplantation (BMT), advantages of UCBT include lower incidence and severity of graft-versus-host disease, easier procurement and prompter availability of cord blood cells, and the possibility of using donors having HLA disparities with the recipient. The large experience accumulated so far has shown that UCBT offers to children a probability of cure at least comparable to that of patients transplanted with bone marrow cells. Since it has been demonstrated that an inverse correlation between the number of nucleated cord blood cells infused per kg recipient body weight and the risk of dying for transplantation-related causes exists, recently developed strategies aimed at increasing the number of cord blood progenitors and at favouring stem cell homing could further optimize the outcome of children with leukemia or other malignancies receiving UCBT. (C) 2010 Elsevier Ltd. All rights reserved.
KW - umbilical cord blood transplantation
KW - childhood acute leukemia
KW - intrabone cord blood transplantation
KW - cell dose
KW - leukemia recurrence
KW - double cord transplantation
KW - umbilical cord blood transplantation
KW - childhood acute leukemia
KW - intrabone cord blood transplantation
KW - cell dose
KW - leukemia recurrence
KW - double cord transplantation
UR - http://hdl.handle.net/10807/251675
U2 - 10.1016/j.beha.2010.06.005
DO - 10.1016/j.beha.2010.06.005
M3 - Article
SN - 1521-6926
VL - 23
SP - 189
EP - 196
JO - BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY
JF - BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY
ER -